![JCM | Free Full-Text | Metronomic Chemotherapy in Pediatric Oncology: From Preclinical Evidence to Clinical Studies JCM | Free Full-Text | Metronomic Chemotherapy in Pediatric Oncology: From Preclinical Evidence to Clinical Studies](https://www.mdpi.com/jcm/jcm-11-06254/article_deploy/html/images/jcm-11-06254-g001.png)
JCM | Free Full-Text | Metronomic Chemotherapy in Pediatric Oncology: From Preclinical Evidence to Clinical Studies
![Metronomic chemotherapy offsets HIFα induction upon maximum‐tolerated dose in metastatic cancers | EMBO Molecular Medicine Metronomic chemotherapy offsets HIFα induction upon maximum‐tolerated dose in metastatic cancers | EMBO Molecular Medicine](https://www.embopress.org/cms/asset/1ce4bc06-596b-44bb-ab79-cd6b8c81bca6/emmm201911416-abs-0001-m.jpg)
Metronomic chemotherapy offsets HIFα induction upon maximum‐tolerated dose in metastatic cancers | EMBO Molecular Medicine
![Metronomic Chemotherapy: Pharmacology and Clinical Applications: 9783662436035: Medicine & Health Science Books @ Amazon.com Metronomic Chemotherapy: Pharmacology and Clinical Applications: 9783662436035: Medicine & Health Science Books @ Amazon.com](https://m.media-amazon.com/images/I/41GBRJb2CoL._AC_SY780_.jpg)
Metronomic Chemotherapy: Pharmacology and Clinical Applications: 9783662436035: Medicine & Health Science Books @ Amazon.com
![Pazopanib based oral metronomic therapy for platinum resistant/refractory epithelial ovarian cancer: A phase II, open label, randomized, controlled trial - Gynecologic Oncology Pazopanib based oral metronomic therapy for platinum resistant/refractory epithelial ovarian cancer: A phase II, open label, randomized, controlled trial - Gynecologic Oncology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/f667fad4-0147-4189-be10-9d13271327b8/gr1_lrg.jpg)
Pazopanib based oral metronomic therapy for platinum resistant/refractory epithelial ovarian cancer: A phase II, open label, randomized, controlled trial - Gynecologic Oncology
![Metronomic Maintenance for High-Risk Pediatric Malignancies: One Size Will Not Fit All: Trends in Cancer Metronomic Maintenance for High-Risk Pediatric Malignancies: One Size Will Not Fit All: Trends in Cancer](https://www.cell.com/cms/attachment/436e6001-0579-4578-9f56-bf266bdf3b02/gr1_lrg.jpg)
Metronomic Maintenance for High-Risk Pediatric Malignancies: One Size Will Not Fit All: Trends in Cancer
![Different mechanisms of action of a metronomic chemotherapy. (modified... | Download Scientific Diagram Different mechanisms of action of a metronomic chemotherapy. (modified... | Download Scientific Diagram](https://www.researchgate.net/publication/269781363/figure/fig2/AS:486208800333826@1492932619617/Different-mechanisms-of-action-of-a-metronomic-chemotherapy-modified-from-127.png)
Different mechanisms of action of a metronomic chemotherapy. (modified... | Download Scientific Diagram
![Indication of metronomic chemotherapy for metastatic breast cancer: clinical outcomes and responsive subtypes Indication of metronomic chemotherapy for metastatic breast cancer: clinical outcomes and responsive subtypes](https://www.spandidos-publications.com/article_images/mco/4/6/mco-04-06-0947-g00.jpg)
Indication of metronomic chemotherapy for metastatic breast cancer: clinical outcomes and responsive subtypes
![Metronomic chemotherapy using orally active carboplatin/deoxycholate complex to maintain drug concentration within a tolerable range for effective cancer management - ScienceDirect Metronomic chemotherapy using orally active carboplatin/deoxycholate complex to maintain drug concentration within a tolerable range for effective cancer management - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0168365916306083-fx1.jpg)
Metronomic chemotherapy using orally active carboplatin/deoxycholate complex to maintain drug concentration within a tolerable range for effective cancer management - ScienceDirect
![JCM | Free Full-Text | Metronomic Chemotherapy for Metastatic Breast Cancer Treatment: Clinical and Preclinical Data between Lights and Shadows | HTML JCM | Free Full-Text | Metronomic Chemotherapy for Metastatic Breast Cancer Treatment: Clinical and Preclinical Data between Lights and Shadows | HTML](https://www.mdpi.com/jcm/jcm-11-04710/article_deploy/html/images/jcm-11-04710-g001.png)
JCM | Free Full-Text | Metronomic Chemotherapy for Metastatic Breast Cancer Treatment: Clinical and Preclinical Data between Lights and Shadows | HTML
![Low-cost oral metronomic chemotherapy versus intravenous cisplatin in patients with recurrent, metastatic, inoperable head and neck carcinoma: an open-label, parallel-group, non-inferiority, randomised, phase 3 trial - The Lancet Global Health Low-cost oral metronomic chemotherapy versus intravenous cisplatin in patients with recurrent, metastatic, inoperable head and neck carcinoma: an open-label, parallel-group, non-inferiority, randomised, phase 3 trial - The Lancet Global Health](https://www.thelancet.com/cms/attachment/e977474a-6e1f-4500-b5df-bcde846c02df/gr1.gif)
Low-cost oral metronomic chemotherapy versus intravenous cisplatin in patients with recurrent, metastatic, inoperable head and neck carcinoma: an open-label, parallel-group, non-inferiority, randomised, phase 3 trial - The Lancet Global Health
Suppressive impact of metronomic chemotherapy using UFT and/or cyclophosphamide on mediators of breast cancer dissemination and invasion | PLOS ONE
Metronomic therapy is an effective salvage treatment for heavily pre-treated relapsed/refractory multiple myeloma | Haematologica
![A phase 1/2 study of metronomic 5-fluorouracil (5-FU) plus nab-paclitaxel, bevacizumab, leucovorin, and oxaliplatin (FABLOx) in patients with metastatic pancreatic cancer - Annals of Oncology A phase 1/2 study of metronomic 5-fluorouracil (5-FU) plus nab-paclitaxel, bevacizumab, leucovorin, and oxaliplatin (FABLOx) in patients with metastatic pancreatic cancer - Annals of Oncology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/asset/a02919d2-957d-41fa-a994-eb1d253a0c09/gr1.jpg)
A phase 1/2 study of metronomic 5-fluorouracil (5-FU) plus nab-paclitaxel, bevacizumab, leucovorin, and oxaliplatin (FABLOx) in patients with metastatic pancreatic cancer - Annals of Oncology
![Metronomic oral vinorelbine in advanced breast cancer and non-small-cell lung cancer: current status and future development | Future Oncology Metronomic oral vinorelbine in advanced breast cancer and non-small-cell lung cancer: current status and future development | Future Oncology](https://www.futuremedicine.com/cms/10.2217/fon.15.306/asset/images/medium/figure2.gif)
Metronomic oral vinorelbine in advanced breast cancer and non-small-cell lung cancer: current status and future development | Future Oncology
![Metronomic chemotherapy: An attractive alternative to maximum tolerated dose therapy that can activate anti-tumor immunity and minimize therapeutic resistance - ScienceDirect Metronomic chemotherapy: An attractive alternative to maximum tolerated dose therapy that can activate anti-tumor immunity and minimize therapeutic resistance - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0304383514007976-can12212-ga-5001.jpg)
Metronomic chemotherapy: An attractive alternative to maximum tolerated dose therapy that can activate anti-tumor immunity and minimize therapeutic resistance - ScienceDirect
![Metronomic and metronomic-like therapies in neuroendocrine tumors – Rationale and clinical perspectives - ScienceDirect Metronomic and metronomic-like therapies in neuroendocrine tumors – Rationale and clinical perspectives - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0305737217300269-gr1.jpg)